Identification of LncRNAs as Therapeutic Targets in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is one kind of blood cancer that has a very heterogeneous biological background, which results in diverse stages the CLL and complex treatment strategies. However, small part tumor may disappear without receiving any treatment. This condition known as “spontaneous regression” occurs result poorly investigated mechanism. Exposing underlying causes this can lead to novel approach for other types cancer. While most such mechanisms have been assumed be directly linked protein coding genes, recent was aimed carry out more comprehensive studies by focusing on non-protein genes well protein-coding at RNA level. In article, we applied in-silico analysis total expression data from 24 samples determine possible regulatory spontaneous regression CLL. These were selected comparing with progressive transcriptional As result, 33 lncRNAs found significantly differentially expressed among these conditions based differential gene analysis. Current study suggested lncRNAs, PTPN22-AS1, PCF11-AS1, SYNGAP1-AS1, PRRT3-AS1 H1FX-AS1 potential therapeutic targets trigger regression. Eventually, presented here reveal new insights into relation non-coding RNAs, particularly lncRNAs.